StemCell Institute (JP:7096)

:7096

7096

StemCell Institute

RESEARCH TOOLSreports

StemCell Institute (7096) Price & Analysis

Compare

0 Followers

7096 Stock Chart & Stats

¥793.00

¥110.00(8.02%)

At close: Jan 08 4:00 PM EST

¥793.00

¥110.00(8.02%)

Day’s Range― - ―

52-Week Range¥744.00 - ¥1,446.00

Previous CloseN/A

Volume70.10K

Average Volume (3M)28.64K

Market Cap

¥8.40B

Enterprise Value¥5.68B

Total Cash (Recent Filing)¥2.71B

Total Debt (Recent Filing)¥497.26M

Price to Earnings (P/E)33.5

Beta0.42

Next Earnings

May 07, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)6.12

Shares Outstanding10,246,600

10 Day Avg. Volume23,150

30 Day Avg. Volume28,640

Financial Highlights & Ratios

PEG Ratio1.47

Price to Book (P/B)5.29

Price to Sales (P/S)5.19

P/FCF Ratio-1.37K

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)14.9

Revenue Forecast (FY)¥2.88B

Bulls Say, Bears Say

Bulls Say

Revenue GrowthConsistent revenue growth (7.97% YoY) indicates the company is expanding market traction and product adoption. Over a 2-6 month horizon this supports predictable top-line momentum, provides operating leverage potential, and underpins reinvestment capacity for R&D or commercialization.

High MarginsRobust gross (63.16%) and EBITDA (25.94%) margins demonstrate durable pricing power and operational efficiency. These margins create a buffer against revenue volatility, enable sustained investment in growth or R&D, and support long-term profitability even if sales growth moderates.

Healthy Capital StructureLow leverage (D/E 0.20) and a solid equity ratio reduce financial risk and preserve strategic optionality. For a biotechnology business with ongoing R&D needs, a conservative balance sheet supports funding flexibility, lowers refinancing risk, and sustains operations through multi-quarter development timelines.

Bears Say

Negative Free Cash FlowNegative free cash flow signals cash burn from operations or heavy capex and can erode liquidity over time. Persisting FCF deficits require external financing or expense cuts, constraining ability to fund R&D, commercial expansion, or dividends without diluting shareholders.

Declining EPSA large negative EPS growth rate (-51%) indicates meaningful deterioration in per-share earnings year-over-year. If sustained, this weakens internal funding capacity, pressures management to cut costs or raise capital, and suggests earnings volatility that can persist across quarters.

Moderate Return On EquityROE of ~14.7% is modest for a growth-focused biotech and implies room to improve capital efficiency. Over the medium term, middling ROE can limit shareholder returns versus peers and suggests the company may not be fully converting equity investments into superior earnings.

StemCell Institute News

StemCell Institute Expands into Southeast Asia with Joint Venture

The latest announcement is out from StemCell Institute ( ($JP:7096) ). StemCell Institute Inc. has entered a joint...

9M ago

7096

7096 FAQ

What was StemCell Institute’s price range in the past 12 months?

StemCell Institute lowest stock price was ¥744.00 and its highest was ¥1446.00 in the past 12 months.

What is StemCell Institute’s market cap?

StemCell Institute’s market cap is ¥8.40B.

When is StemCell Institute’s upcoming earnings report date?

StemCell Institute’s upcoming earnings report date is May 07, 2026 which is in 39 days.

How were StemCell Institute’s earnings last quarter?

StemCell Institute released its earnings results on Feb 12, 2026. The company reported ¥6.12 earnings per share for the quarter, beating the consensus estimate of N/A by ¥6.12.

Is StemCell Institute overvalued?

According to Wall Street analysts StemCell Institute’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does StemCell Institute pay dividends?

StemCell Institute pays a Notavailable dividend of ¥25 which represents an annual dividend yield of N/A. See more information on StemCell Institute dividends here

What is StemCell Institute’s EPS estimate?

StemCell Institute’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does StemCell Institute have?

StemCell Institute has 10,246,600 shares outstanding.

What happened to StemCell Institute’s price movement after its last earnings report?

StemCell Institute reported an EPS of ¥6.12 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.296%.

Which hedge fund is a major shareholder of StemCell Institute?

Currently, no hedge funds are holding shares in JP:7096

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

StemCell Institute

StemCell Institute Inc. engages in the stem cell banking business in Japan. The company is also involved in research and development of medical treatments using stem cells, as well as engages in banking of blood vessel cells businesses. StemCell Institute Inc. was incorporated in 1999 and is headquartered in Tokyo, Japan. StemCell Institute Inc. is a subsidiary of Trim Medical Holdings Inc.